Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
- Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. “We continued to execute our U.S. market launch of Symvess, and in parallel have taken major steps to expand the commercialization of the product to international markets,” said Lau
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Humacyte (HUMA) had its price target lowered by BTIG Research from $6.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateGlobeNewswire
HUMA
Earnings
- 3/27/26 - In-Line
HUMA
Sec Filings
- 3/27/26 - Form 10-K
- 3/24/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- HUMA's page on the SEC website